`571.272.7822
`
`
`
`
`
` Paper No. 46
`
` Entered: July 5, 2016
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`ALTAIRE PHARMACEUTICALS, INC.,
`Petitioner,
`
`v.
`
`PARAGON BIOTECK, INC.,
`Patent Owner.
`____________
`
`Case PGR2015-00011
`Patent 8,859,623 B1
`____________
`
`
`
`Before SHERIDAN K. SNEDDEN and ZHENYU YANG,
`Administrative Patent Judges.
`
`YANG, Administrative Patent Judge.
`
`
`
`
`DECISION
`Petitioner’s Motion to Seal
`37 C.F.R. §§ 42.14, 42.54
`
`
`
`
`
`
`
`
`
`
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`On May 6, 2016, Petitioner filed a motion to seal portions of its Reply
`and Exhibit 1029, and Exhibits 1027, 1028, and 1030 in their entirety. Paper
`34, 1 (“Motion”). Patent Owner has not filed any opposition. Petitioner’s
`Motion is granted.
`According to Petitioner, it seeks to seal portions of the Reply that
`Patent Owner considers highly confidential. Id. at 1 (citing Paper 6, 2).
`Petitioner has filed a redacted version of the Reply. See Paper 34, 2. As
`explained previously and in the concurrently issued Decision on Patent
`Owner’s Motion to Seal, we have determined that Patent Owner has shown
`good cause for sealing confidential and sensitive information related to
`Patent Owner’s financial matters that is not publicly available. Paper 12, 1;
`Paper 45, 2. The redactions to Petitioner’s Reply appear to be limited to
`isolated passages that consist of similar Patent Owner’s confidential
`information. The redactions would not inhibit a reader’s understanding of
`the substance of the Petitioner’s position. Thus, upon considering the
`content of the Reply, we determine that good cause exists for sealing the
`redacted portions of the Reply.
`Petitioner also argues that good cause exists for sealing portions of
`Exhibit 1029, and Exhibits 1027, 1028, and 1030 in their entirety. Paper 34,
`2–4. According to Petitioner, information contained therein “reflects
`proprietary and confidential testing methodologies developed by Petitioner.”
`Id. at 2. Petitioner asserts that these testing methods have not been
`published or otherwise made public, and the disclosure thereof would harm
`Petitioner’s interest. Id. at 3–4. Even though Petitioner has not filed any
`testimonial evidence to support its Motion, we are persuaded that the
`exhibits themselves bear sufficient markings that evince their confidentiality.
`See, e.g., Ex. 1027, 1 (“This document contains information that is
`
`1
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`privileged, confidential and is protected from disclosure under applicable
`law. This document is the sole property of Altaire Pharmaceuticals, Inc.”).
`In addition, Petitioner contends that the Board does not need the
`detailed information Petitioner seeks to seal to make the patentability
`determination in this proceeding. Id. at 4. Further, Petitioner has filed a
`redacted version of Exhibit 1029, redacting only specific information related
`to the testing methodologies. Id. at 3.
`Upon considering the content of Exhibits 1027–1030, along with
`Petitioner’s representations as to the confidentiality of the information
`contained therein, we determine that Petitioner has shown good cause for
`sealing the redacted portions of Exhibit 1029 and Exhibits 1027, 1028, and
`1030 in their entirety.
`
`Accordingly, it is
`ORDERED that Petitioner’s Motion to Seal is GRANTED.
`
`
`
`
`
`
`
`
`
`PETITIONER:
`
`Dipu A. Doshi
`Jonathan W. S. England
`Mark J. Thronson
`BLANK ROME LLP
`DDoshi@BlankRome.com
`JWEngland@BlankRome.com
`MThronson@BlankRome.com
`
`
`
`2
`
`
`
`PGR2015-00011
`Patent 8,859,623 B1
`
`
`PATENT OWNER:
`
`Michael T. Rosato
`Steven W. Parmelee
`Andrew S. Brown
`WILSON SONSINI GOODRICH & ROSATI
`mrosato@wsgr.com
`sparmelee@wsgr.com
`asbrown@wsgr.com
`
`
`
`3
`
`